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TO THE EDITOR
Pathologies associated with genoderma-
toses and other genetic disorders can
irremediably affect fetuses, making
early-stage therapies desirable. Prenatal
maternal drug administration, however,
exposes mothers to potential drug toxi-
city and is limited by the variability in
transplacental drug delivery. Alternative
approaches to fetal treatment should
entail low-risk drug delivery with repro-
ducible pharmacokinetics. X-linked
hypohidrotic ectodermal dysplasia
(XLHED), the most common inherited
disorder of ectoderm development, is
caused by a lack of the signaling mole-
cule ectodysplasin A1 (EDA1), which is
essential for ectodermal placode forma-
tion and subsequent development of
various skin appendages, glands, and
teeth (Mikkola, 2009). Patients with
XLHED have less hair, fewer or no
eccrine sweat, sebaceous and meibo-
mian glands, and malformed or absent
teeth. Insufficient thermoregulation can
lead to perilous hyperthermic episodes
during infancy (Blu¨schke et al., 2010)
and remains an important issue through-
out life (Hammersen et al., 2011). Many
affected individuals suffer from recurrent
airway and eye problems (Dietz et al.,
2013). To date, only symptomatic treat-
ment is available for these patients.
Causative therapeutic approaches to
such disorders are expected to be most
effective if applied already in utero, with
the additional benefit that immune
tolerance of a replacement protein
may be induced, facilitating postnatal
reapplication (Schneider et al., 2002;
Waddington et al., 2003). In the Tabby
mouse, a well-characterized animal
model of XLHED (Falconer, 1952),
prenatal exposure to EDA1 via serial
intravenous administrations to the dam
corrected developmental abnormalities
to a far greater extent compared with
postnatal administration (Gaide and
Schneider, 2003). This approach may,
however, be suboptimal for achieving
reproducible therapeutic drug concen-
trations in human fetuses, and would
expose the mother to high serum levels
of an exogenous molecule. We hypo-
thesized that EDI200, an EDA1 replace-
ment protein consisting of the receptor-
binding domain of EDA1 and the Fc part
of IgG1, may enter the fetal circulation
also after injection into the amniotic
fluid (AF), because the fetus swallows
AF regularly and the neonatal Fc
receptor, which is present in rodent
and human fetal intestine (Shah et al.,
2003), may facilitate intestinal absorp-
tion of Fc-containing proteins. AF could
thus serve as a drug reservoir and
provide for continuous drug uptake.
Here, we report striking reversal of the
XLHED phenotype of Tabby mice
following a single intra-amniotic injec-
tion of EDI200.
Long-term stability of this recombi-
nant protein in AF, i.e. the retention of
binding to its cognate receptor, was
confirmed in vitro under various condi-
tions (Supplementary Figure S1 online).
Pharmacokinetics following intra-
amniotic injection of 35mg EDI200 per
amniotic sac (¼100mg g 1 of estimated
fetal body weight) was studied in wild-
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Figure 1. EDI200 pharmacokinetics after intra-amniotic administration to mice. EDI200 was injected into
amniotic sacs of four pregnant wild-type mice carrying a total of 23 fetuses at day E15 (100mg g1 of
estimated fetal body weight). Some fetuses of each mother were left untreated. Another pregnant mouse
and the fetuses of her served as negative controls. EDI200 serum concentrations were measured at different
time points by receptor-binding ELISA. Highest serum levels were detected 6 hours after the injection.
There was some leakage to untreated siblings and, to a lower extent, into the mother’s circulation. NA, not
applicable; *Po0.05; **Po0.01.
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type mice at day 15 of gestation (E15).
All maternal animals and 93% of the
treated fetuses survived the procedure.
EDI200 serum levels were measured at
different time points after injection both
in treated and untreated fetuses as well
as in the dams. Intra-amniotic injection
of EDI200 resulted in mean fetal serum
levels of 9.0 and 1.2mg ml 1 at 6 and
96 hours, respectively. After 6 hours, this
corresponds to 180 ng of EDI200 per
fetus or 0.5% of the injected protein,
assuming a total serum volume of
approximately 20ml in an E15 mouse
fetus. Interestingly, there was a low level
of EDI200 transfer into the circulation of
untreated siblings and that of the preg-
nant dam (Figure 1). The drug was
partially and slowly redistributed from
treated fetuses, in which EDI200 con-
centration diminished over time, to
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Figure 2. Phenotype after prenatal treatment with EDI200. Tabby mice were treated in utero (E15) by a single intra-amniotic injection of EDI200 (here
100mg g 1) and investigated postnatally. Age-matched native Tabby mice (a) could be distinguished clearly from treated animals (b), which had a darker and
denser coat, showed normal eye opening, retro-auricular and guard hair like wild-type mice, and a hairy, normally shaped tail. Starch–iodine tests of the paws
revealed numerous dark spots in a characteristic pattern indicating functional sweat glands (c). Histological analysis of footpad sections (scale bar¼ 0.5 mm)
confirmed the presence of fully developed eccrine sweat glands in the treated animals (f). Native Tabby mice (d, g) and wild-type mice (e, h) served as controls.
Molars of treated Tabby mice (i) were altogether larger than those of native Tabby mice (j) and showed similar shape and cusps pattern as in wild-type animals (k).
K Hermes et al.
Drug Targeting via Intra-Amniotic Injection
2986 Journal of Investigative Dermatology (2014), Volume 134
untreated siblings that witnessed a
parallel increase in the serum levels
(up to 0.57mg ml 1). Maternal EDI200
serum levels remained o0.1mg ml1
at the time points investigated.
Thus, intra-amniotic administration of
EDI200 at E15 resulted in substantial
fetal uptake with minimal maternal
exposure.
This approach was then evaluated in
pregnant Tabby mice with doses of 100,
10, and 1mg g1 of estimated fetal
body weight. The surgical procedure
was conducted under isofluran anesthe-
sia plus perioperative analgesia with
metamizole and was approved by the
local government authorities. All treated
Tabby mouse fetuses of the high
and intermediate dose cohorts survived
the E15 intra-amniotic injection and
were born without complications. They
were easily distinguishable from native
Tabby mice already in the second
week after birth. Later, normal eye
opening, retro-auricular and guard hair
as in wild-type mice, and a normally
shaped tail tip (Figure 2a and b)
were evident. Starch–iodine tests
revealed regular sweat production at
the paws (Figure 2c–e). Normal eccrine
sweat glands (Figure 2f–h) were
detected in footpads of these animals.
In addition, size and shape of the
molars resembled those of wild-type
mice (Figure 2i–k).
Thus, in contrast to a single maternal
intravenous injection of 400mg of
EDI200 in pregnant Tabby mice at
E15, which corrected the XLHED phe-
notype in the offspring only partially
(unpublished own data), a single
intra-amniotic dose of 3.5mg or above
resulted in complete phenotypic correc-
tion. No adverse effects were observed.
All treated Tabby mice survived to
adulthood and showed normal behavior
and fertility. The lower dose of 1mg g1
body weight yielded only a partial
restoration of normal ectoderm devel-
opment, with less guard and/or tail hair
and fewer sweat glands present (Supple-
mentary Table S1 online). Interestingly,
but less relevant to human singleton
gestations, a dose-dependent correc-
tion was also observed for untreated
littermates (Supplementary Table S1
online)—explained by partial leakage
of the drug to neighboring fetuses. As
expected from previous studies (Gaide
and Schneider, 2003), the maternal
Tabby phenotype was not visibly altered
by EDI200 administration, regardless of
the dose. All dams remained fertile and
no adverse effects of the treatment could
be detected during an observation period
of 6–9 months.
The EDA1 signaling pathway is
well conserved among vertebrates
(Pantalacci et al., 2008) and findings in
animal models should therefore be
transferable to human XLHED patients.
Early corrective treatment would in-
crease their life expectancy, would
have a high impact on the quality of
life, and substantially reduce medical
expenses. Intra-amniotic drug delivery
might be most beneficial if attempted
during mid-gestation, when sweat
gland development is not yet completed
(Ersch and Stallmach, 1999). This
approach is likely to have a good
benefit/risk ratio, supported by the
broad experience with amniocentesis,
and may represent a novel paradigm for
treatment of disorders in early human
development.
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